What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple-agonist peptide developed by Eli Lilly. It targets three key receptors involved in metabolism simultaneously — a first in this drug class.
Retatrutide is the only peptide in development that activates GLP-1, GIP, and glucagon receptors at once. This triple mechanism is why clinical trial results have been unprecedented.
Quick Facts
| Property | Detail |
|---|---|
| Developer | Eli Lilly |
| Mechanism | Triple-agonist (GLP-1 / GIP / Glucagon) |
| Phase | Phase 3 (TRIUMPH-4 topline results Dec 2025) |
| FDA Approved | No |
| Pharmacy Available | No |
| Research Vendor Available | Limited |
How It Compares to Other GLP-1 Peptides
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Brand Names | Ozempic, Wegovy | Mounjaro, Zepbound | N/A (investigational) |
| Receptors Targeted | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| FDA Approved | Yes | Yes | No |
| Max Weight Loss (trials) | ~15% | ~20-22.5% | ~26-29% (Phase 3) |
| Pharmacy Available | Yes | Yes | No |
| Mechanism Count | Single | Dual | Triple |
The glucagon receptor activation is what sets retatrutide apart. While GLP-1 and GIP suppress appetite, the glucagon component actively increases energy expenditure and promotes fat oxidation — adding a calorie-burning element the others lack.
Why the Hype?
Phase 2 trial results published in the New England Journal of Medicine showed 24.2% body weight loss at 48 weeks. The subsequent Phase 3 TRIUMPH-4 trial (68 weeks, results December 2025) exceeded those figures:
- 26.4% average weight loss at the 9 mg dose
- 28.7% average weight loss at the 12 mg dose
- Outperforms semaglutide (~15%) and tirzepatide (~20-22.5%) across all doses
- Dose-dependent response confirmed in both Phase 2 and Phase 3
Current Availability
What You Can Get
- Some research vendors offer retatrutide as a research chemical
- Quality and authenticity vary significantly between sources
What You Cannot Get
- No FDA-approved form exists — pharmacy compounding is not possible
- No legitimate "pharmaceutical grade" retatrutide exists on the market
- Any source marketing it as clinical-grade is misrepresenting the product
COA Requirements for Research Sourcing
- HPLC purity — minimum 95%, preferably 98%+
- Mass spectrometry — confirm molecular identity
- Amino acid sequence verification — critical for complex molecules
- Endotoxin testing — standard for injectable research compounds
The retatrutide molecule is complex and expensive to synthesize properly. If a price seems too good to be true, it almost certainly is. Quality synthesis of triple-agonist peptides costs significantly more than simpler peptides like BPC-157.
Red Flags to Watch For
- Vendors claiming to sell "pharmaceutical grade" retatrutide
- Extremely low prices compared to market averages
- Weight loss claims or human dosing protocols in marketing materials
- No COA provided, or COAs without mass spectrometry data
- Claims of FDA approval or pharmacy-grade sourcing
The Bottom Line
Retatrutide may represent the next major advancement in metabolic peptide therapy, but it is not yet approved and not legally available through pharmacies. Buyers sourcing for research should exercise extreme caution and understand that no quality guarantees exist for gray market products at this stage of development.